Valeant Pharmaceuticals International (VRX) is set to release its earnings on May 9, but earnings might be the last thing investors are worried about.
That's been the takeaway from recent analyst reports previewing Valeant's earnings, including notes from JPMorgan and Wells Fargo, which remains bearish on Valeant's shares. And today, RBC's Douglas Miehm and Joel Hurren, who have a Sector Perform rating on the beaten-down specialty pharmaceutical company, add their voice to the choir:
Shares of Valeant Pharmaceuticals International have gained 1.5% to $9.95 at 9:54 a.m. today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
